Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of MAPK15 protein in prediction of malignancy degree or prognosis degree of prostate cancer

A prostate cancer and protein technology, applied in the direction of measuring devices, instruments, scientific instruments, etc., can solve problems such as death, and achieve strong specificity and obvious effects

Pending Publication Date: 2021-10-15
广州金研生物医药研究院有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although there are currently effective clinical treatments for prostate cancer, such as hormones, surgery, and radiation, there are still many prostate cancer patients who die within 1 to 2 years due to the progression of prostate cancer (biochemical recurrence, postoperative tumor metastasis), Therefore, clinicians urgently need to find better clinical prognostic markers, screen out patients who need further intervention based on markers, and formulate a more appropriate individual treatment plan accordingly

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of MAPK15 protein in prediction of malignancy degree or prognosis degree of prostate cancer
  • Application of MAPK15 protein in prediction of malignancy degree or prognosis degree of prostate cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] An embodiment of the kit for detecting the progress of prostate cancer of the present invention, its composition is as follows:

[0029] Endogenous peroxidase blocking agent (3% hydrogen peroxide solution, purchased from Bebo Biotech) 50ul; animal non-immune serum (5%, purchased from Bebobio) 50ul; the primary antibody is rabbit-derived anti-MAPK15 Polyclonal antibody (purchased from abcam, USA) 1ul; biotin-labeled secondary antibody 50ul; streptavidin-peroxidase 50ul; DAB chromogenic reagent 100ul; phosphate buffered saline (1×PBS buffer, 0.01M) 1000ul.

Embodiment 2

[0031] In this example, the polyclonal antibody staining test of MAPK15 was carried out on the clinical chip samples of prostate cancer patients, and combined with the clinical sample data to further prove that the kit in Example 1 can predict PSA biochemical recurrence, tumor metastasis and Gleason score (GS) after prostate cancer surgery. ), it proves that the kit of the present invention can effectively predict the disease progression of prostate cancer patients.

[0032] The using method of the test kit of embodiment 1, comprises the steps:

[0033] 1) Take out the clinical tissue from the liquid nitrogen, and store the tissue in an embedding box;

[0034] 2) Rinse the tissue continuously with tap water for 5 hours;

[0035] 3) Put it into a Leica automatic dehydrator for tissue dehydration;

[0036] 4) Carry out paraffin embedding tissue;

[0037] 5) Continuously section the embedded paraffin tissue block, with a thickness of about 4 μm;

[0038] 6) Place the cut slic...

Embodiment 3

[0062] According to the TCGA database, the mRNA of MAPK15 in all patients in Example 2 is divided into two groups according to the median, respectively set as high expression group and low expression group, Kaplan-Meier and Log rank method analysis results (see figure 1 ), showing that the high expression of MAPK15 is related to the overall biochemical recurrence-free survival rate of patients (P=0.0006).

[0063] The results of the above clinical verification further show that the kit of Example 1 can display the expression level of the molecular marker MAPK15 used to judge the progression and prognosis of prostate cancer. The kit provided by the present invention is used to detect the expression level of MAPK15 in human prostate tissue, and according to the expression level, it can conveniently and quickly provide assistance for the judgment of malignant progression and prognosis of clinical prostate cancer patients, and provide assistance for disease treatment selection.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of prostate cancer detection, in particular to application of MAPK15 protein in prediction of malignancy degree or prognosis degree of prostate cancer. The invention discloses application of a molecule for detecting MAPK15 protein in preparation of a kit or a detection reagent for predicting the malignancy degree or prognosis degree of prostatic cancer. The invention further discloses a kit for predicting the malignancy degree or prognosis degree of the prostate cancer. The kit comprises an endogenous peroxidase blocking agent, animal non-immune serum, a primary antibody, a biotin-labeled secondary antibody, streptomyces avitin protein-peroxidase, a DAB color developing agent and a phosphate buffer salt solution. The MAPK15 is used as a marker for detecting PSA biochemical recurrence, tumor metastasis and Gleason score (GS) after the prostate cancer operation, and a feasible detection method is provided for predicting prostate cancer progression.

Description

technical field [0001] The invention relates to the technical field of prostate cancer detection, in particular to the application of MAPK15 protein in predicting the malignant degree or prognosis degree of prostate cancer. Background technique [0002] Among male malignant tumors in North America, prostate cancer (PCa) is still the tumor with the highest incidence rate, and its mortality rate is second only to lung cancer. In my country, the incidence of male prostate cancer is increasing year by year, ranking second in male genitourinary system malignant tumors, second only to bladder tumors. Although there are currently effective clinical treatments for prostate cancer, such as hormones, surgery, and radiation, there are still many prostate cancer patients who die within 1 to 2 years due to the progression of prostate cancer (biochemical recurrence, postoperative tumor metastasis), Therefore, clinicians urgently need to find better clinical prognostic markers, based on t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/574G01N33/573
CPCG01N33/57434G01N33/57484G01N33/573G01N2333/912
Inventor 梁应科钟惟德韩兆冬梁宇翔
Owner 广州金研生物医药研究院有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com